Quality of Surveillance Impacts the Colitis-Associated Advanced Neoplasia Risk: A Multicenter Case-Control Study
Although colorectal cancer (CRC) surveillance is embedded in clinical inflammatory bowel disease (IBD) practice, a subset of patients still develops advanced neoplasia (AN) (high-grade dysplasia [HGD] and/or CRC). We aimed to assess the impact of surveillance quality on AN risk in IBD. In this multi...
Gespeichert in:
Veröffentlicht in: | Clinical gastroenterology and hepatology 2024-02, Vol.22 (2), p.357-367.e5 |
---|---|
Hauptverfasser: | , , , , , , , , , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | 367.e5 |
---|---|
container_issue | 2 |
container_start_page | 357 |
container_title | Clinical gastroenterology and hepatology |
container_volume | 22 |
creator | te Groen, Maarten Derks, Monica den Broeder, Nathan Peters, Charlotte Dijkstra, Gerard de Vries, Annemarie Romkens, Tessa Horjus, Carmen de Boer, Nanne de Jong, Michiel Nagtegaal, Iris Derikx, Lauranne Hoentjen, Frank |
description | Although colorectal cancer (CRC) surveillance is embedded in clinical inflammatory bowel disease (IBD) practice, a subset of patients still develops advanced neoplasia (AN) (high-grade dysplasia [HGD] and/or CRC). We aimed to assess the impact of surveillance quality on AN risk in IBD.
In this multicenter case-control study, we searched the Dutch nationwide pathology databank to identify IBD cases with AN and controls with indefinite or low-grade dysplasia. The surveillance colonoscopy preceding the index lesion (first indefinite for dysplasia [IND]/low-grade dysplasia [LGD] or AN) was used to assess the impact of surveillance quality. We assessed intervals, bowel preparation, cecal intubation, and absence of inflammation as primary quality indicators. In addition, we assessed chromoendoscopy, endoscopist expertise, hospital setting, and biopsy strategy. Associations of quality indicators with AN risk were determined with multivariable logistic regression analyses with Firth’s correction.
We included 137 cases and 138 controls. Delayed intervals (58.2% vs 39.6%) and active inflammation (65.3% vs 41.8%) were frequently present in cases and controls and were associated with AN (delayed interval: adjusted odds ratio [aOR], 2.00; 95% confidence interval [CI], 1.07–3.81; P = .03; active inflammation: aOR, 2.46; 95% CI, 1.33–4.61; P < .01). Surveillance compliant with primary quality indicators was associated with a reduced AN risk (aOR, 0.43; 95% CI, 0.22–0.91; P = .03), similar to chromoendoscopy (OR, 0.11; 95% CI, 0.01–0.89; P = .01). Other indicators were not significantly associated with AN.
Surveillance compliant with primary quality indicators is associated with a reduced colitis-associated AN risk. Delayed surveillance intervals and active inflammation were associated with an increased AN risk. This underlines the importance of procedural quality, including endoscopic remission to optimize the effectiveness of endoscopic surveillance.
[Display omitted] |
doi_str_mv | 10.1016/j.cgh.2022.12.010 |
format | Article |
fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2758577171</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S1542356522011776</els_id><sourcerecordid>2758577171</sourcerecordid><originalsourceid>FETCH-LOGICAL-c396t-ba93f31d764dfa82e822a0c74494c11705b78aa0ee795c9a4e9ef575a3298b843</originalsourceid><addsrcrecordid>eNp9kDtv2zAUhYmiQR5OfkCXgmMXqSRFimI7GULbGMgDec0ERV01dGVTISkD_veVYLdjpnuH7xzgfAh9oiSnhJZf17n9_ZozwlhOWU4o-YDOqeAsk5Lyj8e_EKU4Qxcxrglhiit5is6KUkhGKTlHw8Noepf22Hf4aQw7cH1vthbwajMYmyJOr4BrPyEuZssYvXUmQYuX7W7GWnwHfuhNdAY_uvjnG17i27FPzsI2QcC1iZDVfpuC7_FTGtv9JTrpTB_h6ngX6OXnj-f6Oru5_7WqlzeZLVSZssaooitoK0vedqZiUDFmiJWcK24plUQ0sjKGAEglrDIcFHRCClMwVTUVLxboy6F3CP5thJj0xkUL8zrwY9RMikpMniSdUHpAbfAxBuj0ENzGhL2mRM-i9VpPovUsWlOmJ9FT5vOxfmw20P5P_DM7Ad8PAEwjdw6CjtbBrMwFsEm33r1T_xfCuY5r</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2758577171</pqid></control><display><type>article</type><title>Quality of Surveillance Impacts the Colitis-Associated Advanced Neoplasia Risk: A Multicenter Case-Control Study</title><source>MEDLINE</source><source>Elsevier ScienceDirect Journals</source><creator>te Groen, Maarten ; Derks, Monica ; den Broeder, Nathan ; Peters, Charlotte ; Dijkstra, Gerard ; de Vries, Annemarie ; Romkens, Tessa ; Horjus, Carmen ; de Boer, Nanne ; de Jong, Michiel ; Nagtegaal, Iris ; Derikx, Lauranne ; Hoentjen, Frank</creator><creatorcontrib>te Groen, Maarten ; Derks, Monica ; den Broeder, Nathan ; Peters, Charlotte ; Dijkstra, Gerard ; de Vries, Annemarie ; Romkens, Tessa ; Horjus, Carmen ; de Boer, Nanne ; de Jong, Michiel ; Nagtegaal, Iris ; Derikx, Lauranne ; Hoentjen, Frank</creatorcontrib><description>Although colorectal cancer (CRC) surveillance is embedded in clinical inflammatory bowel disease (IBD) practice, a subset of patients still develops advanced neoplasia (AN) (high-grade dysplasia [HGD] and/or CRC). We aimed to assess the impact of surveillance quality on AN risk in IBD.
In this multicenter case-control study, we searched the Dutch nationwide pathology databank to identify IBD cases with AN and controls with indefinite or low-grade dysplasia. The surveillance colonoscopy preceding the index lesion (first indefinite for dysplasia [IND]/low-grade dysplasia [LGD] or AN) was used to assess the impact of surveillance quality. We assessed intervals, bowel preparation, cecal intubation, and absence of inflammation as primary quality indicators. In addition, we assessed chromoendoscopy, endoscopist expertise, hospital setting, and biopsy strategy. Associations of quality indicators with AN risk were determined with multivariable logistic regression analyses with Firth’s correction.
We included 137 cases and 138 controls. Delayed intervals (58.2% vs 39.6%) and active inflammation (65.3% vs 41.8%) were frequently present in cases and controls and were associated with AN (delayed interval: adjusted odds ratio [aOR], 2.00; 95% confidence interval [CI], 1.07–3.81; P = .03; active inflammation: aOR, 2.46; 95% CI, 1.33–4.61; P < .01). Surveillance compliant with primary quality indicators was associated with a reduced AN risk (aOR, 0.43; 95% CI, 0.22–0.91; P = .03), similar to chromoendoscopy (OR, 0.11; 95% CI, 0.01–0.89; P = .01). Other indicators were not significantly associated with AN.
Surveillance compliant with primary quality indicators is associated with a reduced colitis-associated AN risk. Delayed surveillance intervals and active inflammation were associated with an increased AN risk. This underlines the importance of procedural quality, including endoscopic remission to optimize the effectiveness of endoscopic surveillance.
[Display omitted]</description><identifier>ISSN: 1542-3565</identifier><identifier>EISSN: 1542-7714</identifier><identifier>DOI: 10.1016/j.cgh.2022.12.010</identifier><identifier>PMID: 36572110</identifier><language>eng</language><publisher>United States: Elsevier Inc</publisher><subject>Case-Control Studies ; Cecum ; Colitis ; Colitis - pathology ; Colitis, Ulcerative - pathology ; Colon ; Colonic Neoplasms - pathology ; Colonoscopy ; Colorectal Neoplasms - diagnosis ; Colorectal Neoplasms - epidemiology ; Colorectal Neoplasms - etiology ; Crohn’s ; Dysplasia ; Humans ; Hyperplasia - pathology ; Inflammation - pathology ; Inflammatory Bowel Diseases - complications ; Screening</subject><ispartof>Clinical gastroenterology and hepatology, 2024-02, Vol.22 (2), p.357-367.e5</ispartof><rights>2022 AGA Institute</rights><rights>Copyright © 2024 AGA Institute. Published by Elsevier Inc. All rights reserved.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c396t-ba93f31d764dfa82e822a0c74494c11705b78aa0ee795c9a4e9ef575a3298b843</citedby><cites>FETCH-LOGICAL-c396t-ba93f31d764dfa82e822a0c74494c11705b78aa0ee795c9a4e9ef575a3298b843</cites><orcidid>0000-0002-9323-1486</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,27903,27904</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/36572110$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>te Groen, Maarten</creatorcontrib><creatorcontrib>Derks, Monica</creatorcontrib><creatorcontrib>den Broeder, Nathan</creatorcontrib><creatorcontrib>Peters, Charlotte</creatorcontrib><creatorcontrib>Dijkstra, Gerard</creatorcontrib><creatorcontrib>de Vries, Annemarie</creatorcontrib><creatorcontrib>Romkens, Tessa</creatorcontrib><creatorcontrib>Horjus, Carmen</creatorcontrib><creatorcontrib>de Boer, Nanne</creatorcontrib><creatorcontrib>de Jong, Michiel</creatorcontrib><creatorcontrib>Nagtegaal, Iris</creatorcontrib><creatorcontrib>Derikx, Lauranne</creatorcontrib><creatorcontrib>Hoentjen, Frank</creatorcontrib><title>Quality of Surveillance Impacts the Colitis-Associated Advanced Neoplasia Risk: A Multicenter Case-Control Study</title><title>Clinical gastroenterology and hepatology</title><addtitle>Clin Gastroenterol Hepatol</addtitle><description>Although colorectal cancer (CRC) surveillance is embedded in clinical inflammatory bowel disease (IBD) practice, a subset of patients still develops advanced neoplasia (AN) (high-grade dysplasia [HGD] and/or CRC). We aimed to assess the impact of surveillance quality on AN risk in IBD.
In this multicenter case-control study, we searched the Dutch nationwide pathology databank to identify IBD cases with AN and controls with indefinite or low-grade dysplasia. The surveillance colonoscopy preceding the index lesion (first indefinite for dysplasia [IND]/low-grade dysplasia [LGD] or AN) was used to assess the impact of surveillance quality. We assessed intervals, bowel preparation, cecal intubation, and absence of inflammation as primary quality indicators. In addition, we assessed chromoendoscopy, endoscopist expertise, hospital setting, and biopsy strategy. Associations of quality indicators with AN risk were determined with multivariable logistic regression analyses with Firth’s correction.
We included 137 cases and 138 controls. Delayed intervals (58.2% vs 39.6%) and active inflammation (65.3% vs 41.8%) were frequently present in cases and controls and were associated with AN (delayed interval: adjusted odds ratio [aOR], 2.00; 95% confidence interval [CI], 1.07–3.81; P = .03; active inflammation: aOR, 2.46; 95% CI, 1.33–4.61; P < .01). Surveillance compliant with primary quality indicators was associated with a reduced AN risk (aOR, 0.43; 95% CI, 0.22–0.91; P = .03), similar to chromoendoscopy (OR, 0.11; 95% CI, 0.01–0.89; P = .01). Other indicators were not significantly associated with AN.
Surveillance compliant with primary quality indicators is associated with a reduced colitis-associated AN risk. Delayed surveillance intervals and active inflammation were associated with an increased AN risk. This underlines the importance of procedural quality, including endoscopic remission to optimize the effectiveness of endoscopic surveillance.
[Display omitted]</description><subject>Case-Control Studies</subject><subject>Cecum</subject><subject>Colitis</subject><subject>Colitis - pathology</subject><subject>Colitis, Ulcerative - pathology</subject><subject>Colon</subject><subject>Colonic Neoplasms - pathology</subject><subject>Colonoscopy</subject><subject>Colorectal Neoplasms - diagnosis</subject><subject>Colorectal Neoplasms - epidemiology</subject><subject>Colorectal Neoplasms - etiology</subject><subject>Crohn’s</subject><subject>Dysplasia</subject><subject>Humans</subject><subject>Hyperplasia - pathology</subject><subject>Inflammation - pathology</subject><subject>Inflammatory Bowel Diseases - complications</subject><subject>Screening</subject><issn>1542-3565</issn><issn>1542-7714</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2024</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp9kDtv2zAUhYmiQR5OfkCXgmMXqSRFimI7GULbGMgDec0ERV01dGVTISkD_veVYLdjpnuH7xzgfAh9oiSnhJZf17n9_ZozwlhOWU4o-YDOqeAsk5Lyj8e_EKU4Qxcxrglhiit5is6KUkhGKTlHw8Noepf22Hf4aQw7cH1vthbwajMYmyJOr4BrPyEuZssYvXUmQYuX7W7GWnwHfuhNdAY_uvjnG17i27FPzsI2QcC1iZDVfpuC7_FTGtv9JTrpTB_h6ngX6OXnj-f6Oru5_7WqlzeZLVSZssaooitoK0vedqZiUDFmiJWcK24plUQ0sjKGAEglrDIcFHRCClMwVTUVLxboy6F3CP5thJj0xkUL8zrwY9RMikpMniSdUHpAbfAxBuj0ENzGhL2mRM-i9VpPovUsWlOmJ9FT5vOxfmw20P5P_DM7Ad8PAEwjdw6CjtbBrMwFsEm33r1T_xfCuY5r</recordid><startdate>202402</startdate><enddate>202402</enddate><creator>te Groen, Maarten</creator><creator>Derks, Monica</creator><creator>den Broeder, Nathan</creator><creator>Peters, Charlotte</creator><creator>Dijkstra, Gerard</creator><creator>de Vries, Annemarie</creator><creator>Romkens, Tessa</creator><creator>Horjus, Carmen</creator><creator>de Boer, Nanne</creator><creator>de Jong, Michiel</creator><creator>Nagtegaal, Iris</creator><creator>Derikx, Lauranne</creator><creator>Hoentjen, Frank</creator><general>Elsevier Inc</general><scope>6I.</scope><scope>AAFTH</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0002-9323-1486</orcidid></search><sort><creationdate>202402</creationdate><title>Quality of Surveillance Impacts the Colitis-Associated Advanced Neoplasia Risk: A Multicenter Case-Control Study</title><author>te Groen, Maarten ; Derks, Monica ; den Broeder, Nathan ; Peters, Charlotte ; Dijkstra, Gerard ; de Vries, Annemarie ; Romkens, Tessa ; Horjus, Carmen ; de Boer, Nanne ; de Jong, Michiel ; Nagtegaal, Iris ; Derikx, Lauranne ; Hoentjen, Frank</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c396t-ba93f31d764dfa82e822a0c74494c11705b78aa0ee795c9a4e9ef575a3298b843</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2024</creationdate><topic>Case-Control Studies</topic><topic>Cecum</topic><topic>Colitis</topic><topic>Colitis - pathology</topic><topic>Colitis, Ulcerative - pathology</topic><topic>Colon</topic><topic>Colonic Neoplasms - pathology</topic><topic>Colonoscopy</topic><topic>Colorectal Neoplasms - diagnosis</topic><topic>Colorectal Neoplasms - epidemiology</topic><topic>Colorectal Neoplasms - etiology</topic><topic>Crohn’s</topic><topic>Dysplasia</topic><topic>Humans</topic><topic>Hyperplasia - pathology</topic><topic>Inflammation - pathology</topic><topic>Inflammatory Bowel Diseases - complications</topic><topic>Screening</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>te Groen, Maarten</creatorcontrib><creatorcontrib>Derks, Monica</creatorcontrib><creatorcontrib>den Broeder, Nathan</creatorcontrib><creatorcontrib>Peters, Charlotte</creatorcontrib><creatorcontrib>Dijkstra, Gerard</creatorcontrib><creatorcontrib>de Vries, Annemarie</creatorcontrib><creatorcontrib>Romkens, Tessa</creatorcontrib><creatorcontrib>Horjus, Carmen</creatorcontrib><creatorcontrib>de Boer, Nanne</creatorcontrib><creatorcontrib>de Jong, Michiel</creatorcontrib><creatorcontrib>Nagtegaal, Iris</creatorcontrib><creatorcontrib>Derikx, Lauranne</creatorcontrib><creatorcontrib>Hoentjen, Frank</creatorcontrib><collection>ScienceDirect Open Access Titles</collection><collection>Elsevier:ScienceDirect:Open Access</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Clinical gastroenterology and hepatology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>te Groen, Maarten</au><au>Derks, Monica</au><au>den Broeder, Nathan</au><au>Peters, Charlotte</au><au>Dijkstra, Gerard</au><au>de Vries, Annemarie</au><au>Romkens, Tessa</au><au>Horjus, Carmen</au><au>de Boer, Nanne</au><au>de Jong, Michiel</au><au>Nagtegaal, Iris</au><au>Derikx, Lauranne</au><au>Hoentjen, Frank</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Quality of Surveillance Impacts the Colitis-Associated Advanced Neoplasia Risk: A Multicenter Case-Control Study</atitle><jtitle>Clinical gastroenterology and hepatology</jtitle><addtitle>Clin Gastroenterol Hepatol</addtitle><date>2024-02</date><risdate>2024</risdate><volume>22</volume><issue>2</issue><spage>357</spage><epage>367.e5</epage><pages>357-367.e5</pages><issn>1542-3565</issn><eissn>1542-7714</eissn><abstract>Although colorectal cancer (CRC) surveillance is embedded in clinical inflammatory bowel disease (IBD) practice, a subset of patients still develops advanced neoplasia (AN) (high-grade dysplasia [HGD] and/or CRC). We aimed to assess the impact of surveillance quality on AN risk in IBD.
In this multicenter case-control study, we searched the Dutch nationwide pathology databank to identify IBD cases with AN and controls with indefinite or low-grade dysplasia. The surveillance colonoscopy preceding the index lesion (first indefinite for dysplasia [IND]/low-grade dysplasia [LGD] or AN) was used to assess the impact of surveillance quality. We assessed intervals, bowel preparation, cecal intubation, and absence of inflammation as primary quality indicators. In addition, we assessed chromoendoscopy, endoscopist expertise, hospital setting, and biopsy strategy. Associations of quality indicators with AN risk were determined with multivariable logistic regression analyses with Firth’s correction.
We included 137 cases and 138 controls. Delayed intervals (58.2% vs 39.6%) and active inflammation (65.3% vs 41.8%) were frequently present in cases and controls and were associated with AN (delayed interval: adjusted odds ratio [aOR], 2.00; 95% confidence interval [CI], 1.07–3.81; P = .03; active inflammation: aOR, 2.46; 95% CI, 1.33–4.61; P < .01). Surveillance compliant with primary quality indicators was associated with a reduced AN risk (aOR, 0.43; 95% CI, 0.22–0.91; P = .03), similar to chromoendoscopy (OR, 0.11; 95% CI, 0.01–0.89; P = .01). Other indicators were not significantly associated with AN.
Surveillance compliant with primary quality indicators is associated with a reduced colitis-associated AN risk. Delayed surveillance intervals and active inflammation were associated with an increased AN risk. This underlines the importance of procedural quality, including endoscopic remission to optimize the effectiveness of endoscopic surveillance.
[Display omitted]</abstract><cop>United States</cop><pub>Elsevier Inc</pub><pmid>36572110</pmid><doi>10.1016/j.cgh.2022.12.010</doi><orcidid>https://orcid.org/0000-0002-9323-1486</orcidid><oa>free_for_read</oa></addata></record> |
fulltext | fulltext |
identifier | ISSN: 1542-3565 |
ispartof | Clinical gastroenterology and hepatology, 2024-02, Vol.22 (2), p.357-367.e5 |
issn | 1542-3565 1542-7714 |
language | eng |
recordid | cdi_proquest_miscellaneous_2758577171 |
source | MEDLINE; Elsevier ScienceDirect Journals |
subjects | Case-Control Studies Cecum Colitis Colitis - pathology Colitis, Ulcerative - pathology Colon Colonic Neoplasms - pathology Colonoscopy Colorectal Neoplasms - diagnosis Colorectal Neoplasms - epidemiology Colorectal Neoplasms - etiology Crohn’s Dysplasia Humans Hyperplasia - pathology Inflammation - pathology Inflammatory Bowel Diseases - complications Screening |
title | Quality of Surveillance Impacts the Colitis-Associated Advanced Neoplasia Risk: A Multicenter Case-Control Study |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-22T19%3A18%3A52IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Quality%20of%20Surveillance%20Impacts%20the%20Colitis-Associated%20Advanced%20Neoplasia%20Risk:%20A%20Multicenter%20Case-Control%20Study&rft.jtitle=Clinical%20gastroenterology%20and%20hepatology&rft.au=te%20Groen,%20Maarten&rft.date=2024-02&rft.volume=22&rft.issue=2&rft.spage=357&rft.epage=367.e5&rft.pages=357-367.e5&rft.issn=1542-3565&rft.eissn=1542-7714&rft_id=info:doi/10.1016/j.cgh.2022.12.010&rft_dat=%3Cproquest_cross%3E2758577171%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2758577171&rft_id=info:pmid/36572110&rft_els_id=S1542356522011776&rfr_iscdi=true |